Ono Pharmaceutical (OTCMKTS:OPHLF) Announces Quarterly Earnings Results

Ono Pharmaceutical (OTCMKTS:OPHLF) posted its quarterly earnings data on Friday. The company reported $0.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.25 by $0.15, Zacks reports. Ono Pharmaceutical had a return on equity of 8.55% and a net margin of 13.51%.

Ono Pharmaceutical Price Performance

Shares of OPHLF remained flat at $14.61 on Friday. The firm has a 50 day moving average of $14.33 and a two-hundred day moving average of $14.77. Ono Pharmaceutical has a 12 month low of $10.27 and a 12 month high of $18.67. The firm has a market capitalization of $6.87 billion, a price-to-earnings ratio of 14.76 and a beta of 0.34. The company has a current ratio of 3.02, a quick ratio of 2.56 and a debt-to-equity ratio of 0.10.

Analysts Set New Price Targets

Separately, Zacks Research upgraded Ono Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Strong Buy”.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.